Alert message
Alert message
Loading the player...

Contemporary Issues in Relapsed-Refractory Myeloma

Topics include: Treatment
Published on November 2, 2007

Email this program

Get Link

Multiple Myeloma is the second most common hematologic malignancy and is characterized by malignant plasma cells that reproduce uncontrollably. These plasma cells tend to localize within the bone marrow, but they may also be found elsewhere in the body. In this special edition program, Dr. James Berenson joins Andrew to discuss contemporary issues in relapsed-refractory myeloma. Based in Los Angeles, Dr. Berenson is the Founder, President and Chief Executive Officer of the Institute for Myeloma and Bone Cancer Research. He has been involved in many of the major breakthroughs that have brought new treatments for patients with myeloma and resulted in improvements in the length and quality of their lives.

Dr. Berenson speaks in depth about the distinguishing characteristics for each agent used for myeloma treatment, including Revlimid, Velcade (bortezomib), Dexamethasone, Doxil and others, as well as the effectiveness of these drugs in combination therapy. He explains the treatment-free interval, how to re-treat patients with a previous response to certain drugs, his unique take on maintenance therapy, and his approach to treating relapse patients. Hear the latest on Dr. Berenson’s opinion about bone marrow transplant and the debate surrounding it, as well as his answers to questions submitted by listeners.

Listen to this program to learn why Dr. Berenson is so optimistic about multiple myeloma treatment. The rapid advances in research are helping those with multiple myeloma to live longer, better quality lives.

Produced in association with
View more programs featuring

Stay Connected, Sign Up for Alerts!

Be the first to know about new programs and information with email alerts.

Patient Power values your trust and respects your privacy. We will only send you the email you have requested and we will never sell your information to anyone.

See a sample email
Read our full privacy policy
  • Multiple Myeloma


Andrew Schorr:

Hello and thank you for joining us for our special edition program on multiple myeloma. It's the fourth in our series of seven programs we're doing, and we hope it can bring you better information to help you and your family deal with myeloma, connect you with leading experts who are our guests and give you really solid things to discuss with whoever your healthcare provider is. Today we're going to be talking about issues that relate to people who have relapsed with multiple myeloma, are refractory to the treatments that have been available to them. What can you do? And we'll learn more about multiple myeloma in general.

As always, it's important if you have a question, and we know many of you do, that you ask not such a personal question that it puts us in a bind. We can't really practice medicine over the internet, but we want to give you as much guidance as we can and also help all of our listeners.

Now, many of you know a lot about our guest today, and I've known him for years. He's a leading multiple myeloma researcher and specialist, and he's in the clinic every day seeing patients. And that's Dr. James Berenson. Dr. Berenson is the founder, president and chief executive officer of the Institute for Myeloma and Bone Cancer Research. He's based in Los Angeles, and then he deals with cancer doctors across the country for sure and many around the world who are treating people with multiple myeloma.

Dr. Berenson, thank you so much for being with us on Patient Power today.

Dr. Berenson:

You're very welcome. I look forward to the hour we're going to spend together on the telephone.

Related Programs


Page last updated on November 22, 2013